文献速递浆细胞疾病造血干细胞移植与细胞治疗

多发性骨髓瘤自体移植后MRD阴性患者基于细胞遗传学的临床轨迹

Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.
PubMed 文献 · Leukemia · 2026-07-21

该研究分析351例自体干细胞移植后60-100天达到MRD阴性(敏感度2.4×10-6)且基线细胞遗传学可用的新诊断骨髓瘤患者,中位随访50.4个月。尽管均MRD阴性,del(17p)、1q21+、t(4;14)或MAF易位及≥2个高危细胞遗传学异常者无进展生存仍显著劣于标危组,提示早期MRD阴性下高危生物学可能持续存在。

要点

  • ASCT后早期MRD阴性者中,高危细胞遗传学异常仍与更差PFS相关。
  • del(17p)、1q21+、t(4;14)、MAF易位及≥2个高危异常者4年PFS低于标危。
  • 孤立性del(17p)或1q21+也预示PFS劣于标危。

核心结论

  • 在ASCT后早期MRD阴性的骨髓瘤患者中,多种高危细胞遗传学异常(包括孤立性)仍与更差PFS相关。
  • 结果提示即使早期MRD阴性,高危生物学可能持续存在。

研究设计与样本

  • 回顾性分析351例新诊断多发性骨髓瘤患者,均于ASCT后60-100天达到MRD阴性(敏感度2.4×10-6)且基线细胞遗传学数据可用。
  • 中位随访50.4个月;标危细胞遗传学占46%(n=162),1个高危细胞遗传学异常占34%(n=118),≥2个占20%(n=71)。

主要发现

  • 标危组4年PFS为84%。
  • del(17p)者4年PFS 56%(HR 2.89;p=0.0001),1q21+者60%(HR 2.46;p=0.0001),t(4;14)者43%(HR 3.50;p=0.0001),MAF易位[t(14;16)/t(14;20)]者58%(HR 2.51;p=0.01)。
  • 孤立性del(17p)和1q21+也与更差PFS相关。
  • 1个高危细胞遗传学异常者4年PFS 65%(HR 2.31;p=0.0004),≥2个者55%(HR 2.75;p=0.0001)。

临床怎么用

  • ASCT后早期MRD阴性结果应结合基线细胞遗传学风险评估预后。
  • 对携带高危细胞遗传学异常(包括孤立性)的MRD阴性患者,需警惕PFS劣于标危。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) assessment has become central to risk-adapted treatment strategies in multiple myeloma, yet the prognostic value of MRD negativity following autologous stem cell transplantation (ASCT) across individual high-risk cytogenetic abnormalities (HRCAs) remains unclear. We analyzed 351 newly diagnosed patients who achieved MRD negativity (sensitivity 2.4 × 10-6) between day 60-100 following ASCT and had baseline cytogenetic data available. Median follow-up was 50.4 months. Standard-risk cytogenetics were present in 46% (n = 162), while 34% (n = 118) had one HRCA and 20% (n = 71) had ≥2 HRCAs. Despite uniform MRD negativity, several HRCAs continued to confer inferior progression-free survival (PFS). Compared with the standard-risk group (4-year PFS 84%), patients with del(17p), 1q21+, t(4;14), or MAF translocations [t(14;16)/t(14;20)] had significantly lower 4-year PFS rates: 56% (HR 2.89; p = 0.0001), 60% (HR 2.46; p = 0.0001), 43% (HR 3.50; p = 0.0001), and 58% (HR 2.51; p = 0.01), respectively. Isolated del(17p) and 1q21+ also conferred inferior PFS. The 4-year PFS was 65% for patients with one HRCA (HR 2.31; p = 0.0004) and 55% for those with ≥2 HRCAs (HR 2.75; p = 0.0001). In this large MRD-negative post-ASCT cohort, several HRCAs, including isolated HRCAs, were associated with inferior PFS, suggesting a potential persistence of high-risk biology despite early MRD negativity.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mariotti EG, Kumar S, Gonsalves W, et al. Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma. Leukemia. 2026. PMID: 42481797. doi:10.1038/s41375-026-03075-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。